Cost estimates of brain disorders in Belgium

Acta Neurologica Belgica

Volumn 106, Issue 4, 2006, Pages 208-214

  Schoenen, Jean ^a   Gianni, Franco ^b   Schretlen, Luc ^c   Sobocki, Patrik ^d,e  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b ANEIDE ^*  (Belgium)

^c UCB Nv   (Belgium)

^d STOCKHOLM HEALTH ECONOMICS   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Brain disorders; Cost; Health care resources; Pharmacoeconomics; Prevalence

Indexed keywords

ADULT; AGED; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; BELGIUM; BRAIN DISEASE; BRAIN TUMOR; COST OF ILLNESS; DEMENTIA; DEPRESSION; DRUG DEPENDENCE; EPILEPSY; HEADACHE; HEALTH CARE COST; HUMAN; INJURY; MAJOR CLINICAL STUDY; MIGRAINE; MULTIPLE SCLEROSIS; PARKINSON DISEASE; PSYCHOSIS; RESOURCE ALLOCATION; STROKE;

EID: 33846979498     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Andlin-Sobocki P., Jonsson B., Wittchen H. U., Olesen J. Cost of disorders of the brain in Europe. Eur J. Neurol., 2005, 12 (Suppl. 1): 1-27.
2. Andlin-Sobocki P. Economic evidence in addiction: a review. Eur J. Health Econ., 2004, 5 (Suppl. 1): S5-12.
3. Berg J. Economic evidence in migraine and other headaches: a review. Eur J. Health Econ., 2004, 5 (Suppl. 1): S43-54.
4. Berg J. Economic evidence in trauma: a review. Eur. J. Health Econ., 2004, 5 (Suppl. 1): S84-91.
5. Ekman M. Economic evidence in brain tumour: a review. Eur J. Health Econ., 2004, 5 (Suppl. 1): S25-30.
6. Ekman M., Forsgren L. Economic evidence in epilepsy: a review. Eur. J. Health Econ., 2004, 5 (Suppl. 1): S36-42.
7. Ekman M. Economic evidence in stroke: a review. Eur J. Health Econ., 2004, 5 (Suppl. 1): S74-83.
8. Forsgren L., Beghi E., Oun A., Sillanpaa M. The epidemiology of epilepsy in Europe - a systematic review. Eur J. Neurol., 2005, 12: 245-253.
9. Jonsson L. Economic evidence in dementia: a review. Eur J. Health Econ., 2004, 5 (Suppl. 1): S30-35
10. Kobelt G. Economic evidence in multiple sclerosis: a review. Eur J. Health Econ., 2004, 5 (Suppl. 1): S54-62.
11. Lindgren P. Economic evidence in Parkinson's disease: a review. Eur. J. Health Econ., 2004, 5 (Suppl. 1): S63-66.
12. Lothgren M. Economic evidence in affective disorders: a review. Eur J. Health Econ., 2004, 5 (SuppL 1): S12-20.
13. Lothgren M. Economic evidence in anxiety disorders: a review. Eur J. Health Econ., 2004, 5 (Suppl. 1): S20-25.
14. Lothgren M. Economic evidence in psychotic disorders: a review. Eur J. Health Econ., 2004, 5 (Suppl. 1): S67-74.
15. Olesen J., Leonardi M. The burden of brain diseases in Europe. Eur J. Neurol., 2003, 10: 471-477.
16. Pugliatti M., Rosati G., Carton H., Ruse T., Drulovic J., Vécsei L., Milavov I. (2005). The burden of multiple sclerosis in Europe: epidemiological review. Eur. J. Neurol. In press.
17. Scuvee-Moreau J., Kurz X., Dresse A. National Dementia Economic Study Group. The economic impact of dementia in Belgium: results of the National Dementia Economic Study (NADES). Acta Neurol. Belg., 2002, 102: 104-113.
18. Servadei F., Tagliaferri F., Compagnone C., Korsic M., Kraus J. F. (2005). Brain Injury Epidemiology In Europe: Systematic review from recent data. European Journal of Neurosurgery. In press.
19. Stovner L. J., Zwart J.-A., Hagen K., Terwindt G. M., Pascual J. (2005). Epidemiology of Headache in Europe. Eur J. Neurol. In press.
20. Truelsen T., Piechowski-Jozwiak B., Bonita R., Mathers C., Bogousslavsky J., Boysen G. (2005). Stroke incidence and prevalence in Europe: a review of available data. Eur. J. Neurol. In press.
21. Von Campenhausen S., Bornschein B., Wick R., Botzel K., Sampaio C., Poewe W., Oertel W., Siebert U., Berger K, Dodel R. Prevalence and incidence of Parkinson's disease in Europe. Eur. Neuropsychopharmacol., 2005, 15: 473-490.
22. Westphal M., Ekman M., Andlin-Sobocki P., Lönn S., Heese O. (2005). Brain Tumor Epidemiology in the European Union: A Very Critical Review and Quantified Analysis. Acta Neurochirurgica. In press.
23. Wittchen H. U., Jacobi F. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur. Neuropsychopharmacol., 2005, 15: 357-376.